الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

ascendis pharma endocrinology division a/s - lonapegsomatropin - growth and development - hypofysiske og hypotalamiske hormoner og analoger - growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [ghd]),.

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

Øresund pharma aps - ganciclovirnatrium - pulver til koncentrat til infusionsvæske, opløsning - 500 mg

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - antitrombotiske midler - clopidogrel er indiceret hos voksne til forebyggelse af atherothrombotic begivenheder i:patienter med myokardieinfarkt (fra få dage, indtil der er mindre end 35 dage), iskæmisk slagtilfælde (fra 7 dage indtil mindre end 6 måneder) eller etableret perifer arteriel sygdom. for yderligere oplysninger henvises der til afsnit 5.

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 2+0,5 mg

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

g.l. pharma gmbh - buprenorphinhydrochlorid, naloxonhydrochloriddihydrat - resoribletter, sublinguale - 8+2 mg

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

teva b.v.  - lamivudin - hiv infektioner - antivirale midler til systemisk anvendelse - lamivudin teva pharma b. indikeres som en del af antiretroviral kombinationsbehandling til behandling af humane immunsvigt-virus (hiv) -inficerede voksne og børn.

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

aristo pharma gmbh - levetiracetam - oral opløsning - 100 mg/ml

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

europharma.dk aps - budesonid - inhalationspulver - 200 mikrogram/dosis

الدانمرك - الدانماركية - Lægemiddelstyrelsen (Danish Medicines Agency)

europharma.dk aps - budesonid - inhalationspulver - 400 mikrogram/dosis

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiske midler - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.